Literature DB >> 21742557

Combining statins with interferon β in multiple sclerosis: think twice, it might not be all right.

Scott S Zamvil, Lawrence Steinman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21742557      PMCID： PMC4106800          DOI： 10.1016/S1474-4422(11)70153-3

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  10 in total

1.  T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.

Authors:  Robert C Axtell; Brigit A de Jong; Katia Boniface; Laura F van der Voort; Roopa Bhat; Patrizia De Sarno; Rodrigo Naves; May Han; Franklin Zhong; Jim G Castellanos; Robert Mair; Athena Christakos; Ilan Kolkowitz; Liat Katz; Joep Killestein; Chris H Polman; René de Waal Malefyt; Lawrence Steinman; Chander Raman
Journal:  Nat Med       Date:  2010-03-28       Impact factor: 53.440

2.  Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.

Authors:  Martin S Weber; Thomas Prod'homme; Sawsan Youssef; Shannon E Dunn; Cynthia D Rundle; Linda Lee; Juan C Patarroyo; Olaf Stüve; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nat Med       Date:  2007-08-05       Impact factor: 53.440

3.  Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.

Authors:  Mansoureh Togha; Sanaz Ahmadi Karvigh; Masoud Nabavi; Nahid Beladi Moghadam; Mohammad Hossein Harirchian; Mohammad Ali Sahraian; Anahita Enzevaei; Alireza Nourian; Hossein Ghanaati; Kavous Firouznia; Ali Jannati; Majid Shekiba
Journal:  Mult Scler       Date:  2010-05-20       Impact factor: 6.312

4.  Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis.

Authors:  Ajaib S Paintlia; Manjeet K Paintlia; Inderjit Singh; Avtar K Singh
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

5.  Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

Authors:  Per Soelberg Sorensen; Jan Lycke; Juha-Pekka Erälinna; Astrid Edland; Xingchen Wu; Jette Lautrup Frederiksen; Annette Oturai; Clas Malmeström; Egon Stenager; Finn Sellebjerg; Helle Bach Sondergaard
Journal:  Lancet Neurol       Date:  2011-08       Impact factor: 44.182

6.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

7.  Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.

Authors:  Roberta Lanzillo; Giuseppe Orefice; Mario Quarantelli; Carlo Rinaldi; Anna Prinster; Gianluca Ventrella; Daniele Spitaleri; Giacomo Lus; Giovanni Vacca; Barbara Carotenuto; Elena Salvatore; Arturo Brunetti; Gioacchino Tedeschi; Vincenzo Brescia Morra
Journal:  Mult Scler       Date:  2010-02-11       Impact factor: 6.312

8.  Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.

Authors:  Olaf Stüve; Sawsan Youssef; Martin S Weber; Stefan Nessler; Hans-Christian von Büdingen; Bernhard Hemmer; Thomas Prod'homme; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  J Clin Invest       Date:  2006-03-16       Impact factor: 14.808

9.  Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.

Authors:  G Birnbaum; B Cree; I Altafullah; M Zinser; A T Reder
Journal:  Neurology       Date:  2008-06-04       Impact factor: 9.910

10.  Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis.

Authors:  Friedemann Paul; Sonia Waiczies; Jens Wuerfel; Judith Bellmann-Strobl; Jan Dörr; Helmar Waiczies; Mareile Haertle; Klaus D Wernecke; Hans-Dieter Volk; Orhan Aktas; Frauke Zipp
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240
  10 in total
  5 in total

Review 1.  The Evolving Mechanisms of Action of Glatiramer Acetate.

Authors:  Thomas Prod'homme; Scott S Zamvil
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

2.  Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study.

Authors:  E Waubant; D Pelletier; M Mass; J A Cohen; M Kita; A Cross; A Bar-Or; T Vollmer; M Racke; O Stüve; S Schwid; A Goodman; N Kachuck; J Preiningerova; B Weinstock-Guttman; P A Calabresi; A Miller; M Mokhtarani; D Iklé; S Murphy; H Kopetskie; L Ding; E Rosenberg; C Spencer; S S Zamvil
Journal:  Neurology       Date:  2012-03-28       Impact factor: 9.910

Review 3.  Therapeutic decisions in multiple sclerosis: moving beyond efficacy.

Authors:  Wolfgang Brück; Raff Gold; Brett T Lund; Celia Oreja-Guevara; Alexandre Prat; Collin M Spencer; Lawrence Steinman; Mar Tintoré; Timothy L Vollmer; Martin S Weber; Leslie P Weiner; Tjalf Ziemssen; Scott S Zamvil
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

4.  Interference with RhoA-ROCK signaling mechanism in autoreactive CD4+ T cells enhances the bioavailability of 1,25-dihydroxyvitamin D3 in experimental autoimmune encephalomyelitis.

Authors:  Ajaib S Paintlia; Manjeet K Paintlia; Bruce W Hollis; Avtar K Singh; Inderjit Singh
Journal:  Am J Pathol       Date:  2012-07-13       Impact factor: 4.307

5.  Glatiramer acetate treatment negatively regulates type I interferon signaling.

Authors:  Nicolas Molnarfi; Thomas Prod'homme; Ulf Schulze-Topphoff; Collin M Spencer; Martin S Weber; Juan C Patarroyo; Patrice H Lalive; Scott S Zamvil
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-11-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.